The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| UNH | -46.4% | -10.29% | -2.15% | +113,001% |
| S&P | +15.58% | +78.13% | +12.24% | +3,606% |
A health insurance giant, UnitedHealth Group serves more than 75 million people worldwide.
The stock has already declined 16% this year.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $113.22B | 12.3% |
| Market Cap | $299.03B | -35.8% |
| Market Cap / Employee | $747.57K | 0.0% |
| Employees | 400K | 0.0% |
| Net Income | $218.00M | -96.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $28.12B | 11.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $72.32B | -5.1% |
| Short Term Debt | $6.07B | 9.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.94% | -1.0% |
| Return On Invested Capital | 13.41% | -1.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $160.00M | -89.0% |
| Operating Free Cash Flow | $1.11B | -53.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 21.89 | 13.51 | 18.02 | 25.02 | -23.14% |
| Price to Book | 5.17 | 2.99 | 3.30 | 3.12 | -36.78% |
| Price to Sales | 1.17 | 0.67 | 0.72 | 0.67 | -42.71% |
| Price to Tangible Book Value | -12.83 | -8.00 | -8.81 | -8.01 | -39.89% |
| Price to Free Cash Flow TTM | 28.04 | 16.23 | 32.91 | 36.82 | 3.42% |
| Free Cash Flow Yield | 3.6% | 6.2% | 3.0% | 2.7% | -3.31% |
| Return on Equity | 15.9% | 24.3% | 23.1% | 18.5% | 15.56% |
| Total Debt | $81.27B | $79.19B | $80.14B | $78.39B | -4.16% |
Our hosts share their perspectives on the positioning of the latest iPhone 12 devices.
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
Insurers report strong Q1 results despite Obamacare losses; Fresenius plants an Akorn; and Express Scripts' battle with Anthem gets real.
A cancer drugmaker, a marijuana drug researcher, and an insurer are serving up tasty performance this holiday season.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
